Prosecution Insights
Last updated: April 19, 2026
Application No. 18/247,795

METHOD FOR PRODUCING CARBONYLAMINOFURANS

Non-Final OA §112
Filed
Apr 04, 2023
Examiner
OH, TAYLOR V
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BAYER AKTIENGESELLSCHAFT
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
2y 5m
To Grant
96%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
1415 granted / 1742 resolved
+21.2% vs TC avg
Strong +15% interview lift
Without
With
+15.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
35 currently pending
Career history
1777
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
33.6%
-6.4% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
37.3%
-2.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1742 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Non-Final Rejection The Status of Claims: Claims 1-9 are pending. Claims 1-9 are rejected. Claims 1-6 and 8 are objected. DETAILED ACTION 1. Claims 1-9 are under consideration in this Office Action. Priority 2. It is noted that this application is a 371 of PCT/EP2021/077319 10/04/2021 , which has a foreign priority document, EPO EP20200255.6 10/06/2020. Drawings 3. None. IDS 4. None. Claim Objections Claims 1-6, 8 are objected to because of the following informalities: In claims 1-6, 8, the term “general” of the general formula is recited. This expression can be improper because the claims do not define how general the formula can be in the claims. The examiner recommends to remove the term” general” from the claims. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. In claim 1-2, the portion “ Tol” of the ” p-TolSO2O” as the definition of the variable “X” is recited. This expression can be vague because the meaning of “Tol” could be interpreted differently. The examiner recommends to replace “Tol” with its proper chemical structure in the claim. The Close Prior Art The close prior art to the current invention is Brucoli et al (Bioorg. Med. Chem. 20 (2012) 2019–2024) which describes the following scheme: PNG media_image1.png 200 400 media_image1.png Greyscale . However, is Brucoli et al does not teach the stating material and intermediate compounds to produce the final product. So, it would have been unobvious over the claimed invetrion. Conclusion Claims 1-9 are rejected. Claims 1-6 and 8 are objected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TAYLOR V OH whose telephone number is (571)272-0689. The examiner can normally be reached 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TAYLOR V OH/Primary Examiner, Art Unit 1625 10/12/2025
Read full office action

Prosecution Timeline

Apr 04, 2023
Application Filed
Oct 12, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599614
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF MICROBIAL INFECTIOUS DISEASES AND ASSOCIATED INFLAMMATORY DISORDERS AND FOR THE TREATMENT AND PROPHYLAXIS OF AGING AND ASSOCIATED DISEASES
2y 5m to grant Granted Apr 14, 2026
Patent 12600724
INDOLE ALKALOID AND PREPARATION METHOD AND USE THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12594279
COMPOSITION FOR PREVENTING OR TREATING TNF-alpha-RELATED DISEASE, COMPRISING HYDROFLUMETHIAZIDE AS ACTIVE INGREDIENT
2y 5m to grant Granted Apr 07, 2026
Patent 12595240
PROCESS FOR THE PRODUCTION OF ETHYLENE OXIDE
2y 5m to grant Granted Apr 07, 2026
Patent 12582649
COMPOSITIONS AND METHODS FOR HAIR FOLLICLE REGENERATION
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
96%
With Interview (+15.3%)
2y 5m
Median Time to Grant
Low
PTA Risk
Based on 1742 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month